Patrick G. LePore is a businessperson who has been at the head of 6 different companies and currently holds the position of Independent Non-Executive Chairman at Lannett Co., Inc., Chairman at Lautus Pharmaceuticals LLC and Chairman at Endo Generics Holdings, Inc. He is also on the board of Matinas BioPharma Holdings, Inc., Villanova University, Tyme, Inc. and VYNE Therapeutics, Inc.
In his past career Patrick G. LePore occupied the position of Chairman for AgeneBio, Inc., President-Healthcare Marketing Group at Cardinal Health, Inc. and Chairman, President & Chief Executive Officer at Boron, LePore & Associates, Inc. (a subsidiary of Cardinal Health, Inc.) and Chairman, President & Chief Executive Officer of Par Pharmaceutical, Inc.
Patrick G. LePore received an undergraduate degree from Villanova University and an MBA from Fairleigh Dickinson University.
What is Patrick G. LePore's net worth?
The estimated net worth of Patrick G. LePore is at least $95,223.20 as of January 15th, 2025. Mr. LePore owns 51,472 shares of VYNE Therapeutics stock worth more than $95,223 as of March 13th. This net worth evaluation does not reflect any other investments that Mr. LePore may own. Learn More about Patrick G. LePore's net worth.
How do I contact Patrick G. LePore?
The corporate mailing address for Mr. LePore and other VYNE Therapeutics executives is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. VYNE Therapeutics can also be reached via phone at (800) 755-7936 and via email at jallaire@lifesciadvisors.com. Learn More on Patrick G. LePore's contact information.
Has Patrick G. LePore been buying or selling shares of VYNE Therapeutics?
During the last quarter, Patrick G. LePore has bought $43,800.00 of VYNE Therapeutics stock. Most recently, on Wednesday, January 15th, Patrick G. Lepore bought 15,000 shares of VYNE Therapeutics stock. The stock was acquired at an average cost of $2.92 per share, with a total value of $43,800.00. Following the completion of the transaction, the director now directly owns 51,472 shares of the company's stock, valued at $150,298.24. Learn More on Patrick G. LePore's trading history.
Are insiders buying or selling shares of VYNE Therapeutics?
During the last year, VYNE Therapeutics insiders bought shares 1 times. They purchased a total of 15,000 shares worth more than $43,800.00. The most recent insider tranaction occured on January, 15th when Director Patrick G Lepore bought 15,000 shares worth more than $43,800.00. Insiders at VYNE Therapeutics own 4.8% of the company.
Learn More about insider trades at VYNE Therapeutics. Information on this page was last updated on 1/15/2025.
